Publications by authors named "Rebecca Crudale"
Article Synopsis
- Plasmodium vivax is increasingly problematic in tropical regions, particularly where Plasmodium falciparum is declining, due to its ability to cause relapse infections that hinder treatment efforts.
- Researchers developed four specialized molecular inversion probe (MIP) genotyping panels targeting key genetic variations in P. vivax, aiming to better understand its population structure and resistance mechanisms.
- Analysis using these panels on 866 infections in the Peruvian Amazon revealed significant findings, including transmission networks, gene mutations related to drug resistance, and potential vaccine targets, suggesting these tools can enhance research and control of P. vivax globally.
Most malaria rapid diagnostic tests (RDTs) detect histidine-rich protein 2 (PfHRP2) and PfHRP3, but deletions of and genes make parasites undetectable by RDTs. We analyzed 19,313 public whole-genome-sequenced field samples to understand these deletions better. deletion only occurred by chromosomal breakage with subsequent telomere healing.
View Article and Find Full Text PDFArticle Synopsis
- In 2014, a significant mutation linked to artemisinin resistance, known as K13 561H, was first detected in Rwanda, making it crucial to monitor its spread.
- Researchers utilized advanced blood preservation and pooled sequencing methods to assess the frequency of this mutation across multiple sites in Rwanda and neighboring countries from May 2022 to March 2023.
- Results showed that K13 561H and 675V mutations were prevalent in Rwanda, with concerning additional mutations emerging, signaling threats to malaria treatment efficacy and control efforts in the region.
Novel antimalarials are urgently needed to combat rising resistance to available drugs. The imidazolopiperazine ganaplacide is a promising drug candidate, but decreased susceptibility of laboratory strains has been linked to polymorphisms in the cyclic amine resistance locus (PfCARL), acetyl-CoA transporter (PfACT), and UDP-galactose transporter (PfUGT). To characterize parasites causing disease in Africa, we assessed drug susceptibilities to ganaplacide in 750 .
View Article and Find Full Text PDFBackground: Given the altered responses to both artemisinins and lumefantrine in Eastern Africa, monitoring antimalarial drug resistance in all African countries is paramount.
Methods: We measured the susceptibility to six antimalarials using growth inhibition assays (IC) for a total of 805 isolates obtained from travelers returning to France (2016-2023), mainly from West and Central Africa. Isolates were sequenced using molecular inversion probes (MIPs) targeting fourteen drug resistance genes across the parasite genome.
Given the altered responses to both artemisinins and lumefantrine in Eastern Africa, monitoring antimalarial drug resistance in all African countries is paramount. We measured the susceptibility to six antimalarials using growth inhibition assays (IC ) for a total of 805 isolates obtained from travelers returning to France (2016-2023), mainly from West and Central Africa. Isolates were sequenced using molecular inversion probes (MIPs) targeting fourteen drug resistance genes across the parasite genome.
View Article and Find Full Text PDFArticle Synopsis
- Transmission of malaria is on the rise in tropical regions and poses challenges for treatment, leading to relapse infections.
- Researchers developed four specialized molecular inversion probe (MIP) genotyping panels to analyze genetic variations related to antimalarial resistance and vaccines, focusing on specific SNPs.
- The study analyzed 866 malaria infections in the Peruvian Amazon, identifying key transmission networks and genetic features that could enhance malaria control efforts in other affected areas.
Newly arrived refugees offer insights into malaria epidemiology in their countries of origin. We evaluated asymptomatic refugee children within 7 days of arrival in Uganda from South Sudan and the Democratic Republic of Congo (DRC) in 2022 for parasitemia, parasite species, and Plasmodium falciparum drug resistance markers. Asymptomatic P.
View Article and Find Full Text PDFArticle Synopsis
- The first detection of the K13 artemisinin resistance mutation 561H occurred in Rwanda, highlighting the need for ongoing surveillance in East Africa as new mutations emerge.
- A study involved collecting malaria-positive samples from 39 health facilities across Rwanda, Uganda, Tanzania, and the DRC, revealing high frequencies of mutations 561H and 675V in Rwanda, indicating significant resistance levels.
- The presence of candidate mutations, alongside other known resistance markers, suggests a concerning trend of increasing drug resistance in the region, potentially threatening malaria treatment effectiveness.
Background: Partial resistance of to the artemisinin component of artemisinin-based combination therapies, the most important malaria drugs, emerged in Southeast Asia and now threatens East Africa. Partial resistance, which manifests as delayed clearance after therapy, is mediated principally by mutations in the kelch protein K13 (PfK13). Limited longitudinal data are available on the emergence and spread of artemisinin resistance in Africa.
View Article and Find Full Text PDF